New Delhi: Drug firm Zydus Cadila said on Friday it had received limited emergency use approval from the Indian Drug Regulator for the use of Pegylated Interferon alpha-2b (PegIFN) for the treatment of moderate COVID-19 infection in adults.
Earlier this month, the company sought approval from the DCGI for the additional indication of the hepatitis Pegylated Interferon Alpha-2b for treatment. COVID-19.
The company has received limited emergency use approval from the Drug Control General of India (DCGI) for the use of ‘Virafin’, PegIFN for the treatment of moderate COVID-19 infection in adults, Zydus Cadila said in a regulatory submission. PegIFN has for many years established well-established safety with multiple doses in chronic hepatitis B and C patients.
A single dose of subcutaneous treatment of the antiviral Virafin will make the treatment more comfortable for the patients. When administered early during COVIDVirafin will help patients recover faster and avoid many of the complications. It will be available on prescription from a medical specialist for use in a hospital / institution, Zydus Cadila said.
‘The fact that we can offer a therapy that significantly reduces the virus load if we are administered early can help with disease management. It comes at a much-needed time for patients and we will continue to give them access to critical therapies in this fight against COVID-19, ”Said Sharvil Patel, managing director of Cadila Healthcare.
Shares of Cadila Healthcare, the listed entity of the Zydus Group, closed at BSE 571.20 per thesis, up 3.43 percent from the previous close.
Source: Telangana Today